Arca
Skip to content

Glioma

Drug research and approvals for glioma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 575 studies of glioma are recruiting on ClinicalTrials.gov, Health Canada has authorized 29 drug trials for it since 2013, FDA has 12 approved and 171 open orphan designations naming it, and the EU has 9 authorised medicines for it.

  • Recruiting worldwide: 575
  • Trials authorized in Canada: 29
  • FDA orphan approvals: 12
  • EU medicines: 9

Recruiting Now

Newest start dates first, of 575 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

The 10 newest of 29; search them all in Canada trials
Aug 20, 2026A phase 3, multicenter, clinical study to evaluate the efficacy and safety of safusidenib erbumine in participants with isocitrate dehydrogenase 1…SAFUSIDENIB (AB-218, DS-1001B)Nuvation BioPending
Jul 3, 2026Microscopic mapping of gadolinium in human glioma to define the tissue basis of radiographic enhancementGADOBUTROLMCGILL UNIVERSITYPending
Mar 24, 2026A phase II trial of act001 in children and adolescents with diffuse intrinsic pontine gliomas and h3k27-altered high grade gliomasACT001COLLABORATIVE NETWORK FOR NEURO-ONCOLOGY CLINICAL TRIALS (CONNECT)Ongoing
Jun 4, 2025A phase 1/2 study of mirdametinib and vinblastine for newly diagnosed or previously untreated patients with pediatric low-grade glioma and activation of the…MIRDAMETINIB / VINBLASTINECENTRE HOSPITALIER UNIVERSITAIRE SAINTE-JUSTINEOngoing
Mar 4, 2025Phase 2 study of ribociclib-containing post-radiotherapy combinations in pediatric and young adult patients newly diagnosed with high-grade glioma (hgg),…EVEROLIMUS / RIBOCICLIBCOLLABORATIVE NETWORK FOR NEURO-ONCOLOGY CLINICAL TRIALS (CONNECT)Pending
Feb 28, 2025A phase II study evaluating the safety, efficacy, and intracranial activity of tarlatamab in recurrent/refractory gliomas with idh mutation (targid)IMDELLTRAUNIVERSITY HEALTH NETWORKOngoing
Aug 20, 2024Assessment of safety and feasibility of fus next generation dome helmet mediated blood-brain barrier disruption for the treatment of high-grade glioma in…PERFLUTREN (PERFLUOROPROPANE)SUNNYBROOK RESEARCH INSTITUTEOngoing
Jun 13, 2024U-r-immune glioma (ca209-1245): a pilot study investigating upfront adaptive immunotherapy approach in children, adolescent and young adult (caya) patients…OPDIVOTHE HOSPITAL FOR SICK CHILDRENOngoing
Dec 13, 2023A pilot study to investigate safety and efficacy of weekly combination of intravenous vinblastine with oral type ii raf inhibitor tovorafenib in pediatric…TOVORAFENIB (DAY 101)THE HOSPITAL FOR SICK CHILDRENOngoing
Feb 28, 2023Onc201 for the treatment of newly diagnosed h3 k27m-mutant diffuse glioma following completion of radiotherapy: a randomized, double-blind, placebo-controlled,…DORDAVIPRONE (ONC201)ChimerixOngoing

FDA Orphan Designations

Approved first, then open designations, newest first; 15 of 183
Sep 11, 2026Pixclarafor use with positron emission tomography (PET) to differentiate recurrent or progressive glioma from treatment-related change, in…Telix Pharmaceuticals Limited (Telix)Approved
Aug 6, 2025Modeysotreatment of adult and pediatric patients 1 year of age and older with diffuse midline glioma harboring an H3 K27M mutation with…Chimerix, Inc.Approved
Aug 6, 2024Voranigotreatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible isocitrate…Servier Pharmaceuticals LLCApproved
Apr 23, 2024Ojemdatreatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or…Day One Biopharmaceuticals, Inc.Approved
Mar 16, 2023Mekinistin combination with dabrafenib, for the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF…Novartis Pharmaceuticals CorporationApproved
Mar 16, 2023Tafinlarin combination with trametinib, for the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF…Novartis Pharmaceuticals CorporationApproved
Jun 6, 2017GleolanOptical imaging agent indicated in patients with glioma (suspected World Health Organization Grades III or IV on preoperative imaging) as…NX Development CorporationApproved
May 5, 2009AvastinTreatment of glioblastoma with progressive disease following prior therapyGenentech, Inc.Approved
Mar 15, 2005TemodarTreatment of adult patients with newly diagnosed glioblastoma multiforme concomitatly with radiotherapy and then as maintenance treatmentSchering-Plough Research InstituteApproved
Feb 25, 2003GliadelExpanding the indication to include patients with malignant glioma undergoing primary surgical resection.Guilford Pharmaceuticals, Inc.Approved
Aug 11, 1999TemodarTreatment of adult patients with refractory anaplastic astrocytoma, i.e., patients at first relapse who have experienced disease…Schering-Plough Research InstituteApproved
Sep 23, 1996GliadelAs an adjunct to surgery to prolong survival in patients with recurrent glioblastoma multiforme for whom surgical resection is indicatedGuilford Pharmaceuticals, Inc.Approved
Sep 21, 2026Allogeneic gamma delta T cells modified by messenger RNA…treatment of malignant gliomaEver Supreme Bio Technology Co., Ltd.Designated
Aug 27, 2026reversible, adenosine triphosphate (ATP) competitive…treatment of malignant gliomaBiomed Valley Discoveries Inc.Designated
Jul 13, 2026co-packaged combination of perillyl alcohol and…treatment of the malignant gliomaCuratio Therapeutics, LLCDesignated

Medicines Authorised in the EU

Newest first
Apr 20, 2026Ojemdatovorafenib · orphanIpsen PharmaEMA ↗
Jan 5, 2024Spexotrastrametinib · orphanNovartis Europharm LimitedEMA ↗
Nov 15, 2023Finleedabrafenib · orphanNovartis Europharm LimitedEMA ↗
Jul 13, 2011Temozolomide Suntemozolomide · genericSun Pharmaceutical Industries Europe B.V.EMA ↗
Mar 15, 2010Temozolomide Accordtemozolomide · genericAccord Healthcare S.L.U.EMA ↗
Jan 28, 2010Temozolomide Tevatemozolomide · genericTeva B.V.EMA ↗
Jan 25, 2010Temomedactemozolomide · genericmedac Gesellschaft für klinische Spezialpräparate mbHEMA ↗
Sep 7, 2007Gliolan5-aminolevulinic acid hydrochloridePhotonamic GmbH & Co. KGEMA ↗
Jan 26, 1999TemodaltemozolomideMerck Sharp & Dohme B.V.EMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.